News

Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions

CAMBRIDGE, Mass., July 10, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced additions to its leadership team through key…

1 year ago

Hospital Systems Launch Into Digital MSK With MedBridge

New Pathways Offering Increases Access to MSK Care and Enables Patients to Remain In-NetworkSEATTLE, WA / ACCESSWIRE / July 10,…

1 year ago

Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program

REDWOOD CITY, CA / ACCESSWIRE / July 10, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the…

1 year ago

Bemax Receives Kroger’s Invitation to Attend Supplier’s Diversity for Vendors

Dallas, Georgia--(Newsfile Corp. - July 10, 2024) - Bemax Inc. (OTC Pink: BMXC), a private label development company with a…

1 year ago

Global Health Intelligence Announches the Best-Equipped Hospitals in Latin America for 2024

GHI Provides a Complimentary Guide Outlining the Region's Hospitals, Clinics and Other Facilities With the Highest Numbers of Essential Medical…

1 year ago

Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live…

1 year ago

Interactive Strength Inc. (Nasdaq:TRNR) Regains Compliance with Nasdaq Listing Rule about Minimum Bid Price

AUSTIN, TX / ACCESSWIRE / July 10, 2024 / Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or "the Company"), maker of innovative…

1 year ago

Two USOSM Partner Practices Receive AAAHC Accreditation

Recognition Enables Oral and Maxillofacial Surgery Centers of Excellence DistinctionIRVING, Texas, July 10, 2024 (GLOBE NEWSWIRE) -- The Accreditation Association…

1 year ago

BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental healthMALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc.…

1 year ago

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

Skyhawk’s SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose tested in…

1 year ago